Ricordel, Charles http://orcid.org/0000-0001-6160-2732
Chaillot, L.
Vlachavas, E. I.
Logotheti, M.
Jouannic, A.
Desvallees, T.
Lecuyer, G.
Aubry, M.
Kontogianni, G.
Mastrokalou, C.
Jouan, F.
Jarry, U.
Corre, R.
Le Guen, Y.
Guillaudeux, T.
Lena, H.
Chatziioannou, A.
Pedeux, Rémy http://orcid.org/0000-0002-2553-7934
Article History
Received: 23 August 2022
Accepted: 24 February 2023
First Online: 3 March 2023
Competing interests
: CR declare personal and institutional financial interest as invited speaker for Takeda, Astrazeneca, as advisory role for BMS, MSD and Takeda; LC declare no conflict of interest; EIV declare no conflict of interest; ML declare no conflict of interest; AJ declare no conflict of interest; TD declare no conflict of interest; GL declare no conflict of interest; MA declare no conflict of interest; GK declare no conflict of interest; CM declare no conflict of interest; FJ declare no conflict of interest; UJ declare no conflict of interest; RC personal interest as invited speaker for BMS, as consulting or advisory role for Takeda, Lilly, Sanofi and Astrazeneca; YLG declare no conflict of interest; TG declare personal and institutional financial interest as member of the board of directors of Kineta; HL declare personal financial interest as honoraria recipient for BMS, Astrazeneca, MSD, Pfizer, Sandoz, as consulting or advisory role for Astrazeneca, Pfizer, Sanofi, Daiichi Sankyo/Lilly, Novartis and Roche; AC declare personal and institutional financial interest as CEO of e-NIOS Applications PC; RP declare no conflict of interest; CTC-CPC study was initially funded by the JOTGO 2015 research grant with CR as a recipient.